UBQLN1 and laryngotracheoesophageal cleft: Section 1 includes (a) sera from 212 LC patients, 144 BLD patients and 212 NC was used to test the level of anti-UBQLN1 in validation cohort 1; (b) 210 PN patients’ samples were utilized to detect the expression of anti-UBQLN1 in validation cohort 2; (c) 118 PN patients with the results of CEA, CYFRA211, CA125 and 12 CT indicators was applied to construct the discrimination model of PN patients and evaluate the diagnostic ability of this model in patients with several clinical characteristics.